title: Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect.
abstract: Allogeneic hematopoietic cell transplantation (allo-HCT) represents the only curative therapy for many haematological malignancies. Its curative potential is mostly attributed to the graft-versus-leukemia effect (GvL), which is mainly driven by donor T-cells. Donor lymphocyte infusions (DLI), likewise a second allo-HCT, have become a standard approach to treat AML and MDS relapses post allo-HCT. Although DLI have been used in this setting for decades, its effectivity and toxicity are still unpredictable in many patients. Over these recent years, new DLI strategies and therapies have been developed for AML and MDS. In this review, we will overview the recent use of DLI for AML and MDS, with up to date information from novel studies and research lines.
authors.affiliation: Hematopoietic Cell Transplant Program, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain. Electronic address: gorti@vebron.net.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Orti
authors.affiliation: Hematopoietic Cell Transplant Program, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain.
authors.forename: Pere
authors.initials: P
authors.lastname: Barba
authors.affiliation: Hematopoietic Cell Transplant Program, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Fox
authors.affiliation: Hematopoietic Cell Transplant Program, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain.
authors.forename: Olga
authors.initials: O
authors.lastname: Salamero
authors.affiliation: Hematopoietic Cell Transplant Program, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain.
authors.forename: Francesc
authors.initials: F
authors.lastname: Bosch
authors.affiliation: Hematopoietic Cell Transplant Program, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain.
authors.forename: David
authors.initials: D
authors.lastname: Valcarcel
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy; D006086:Graft vs Host Disease / Q000209:etiology; D020544:Graft vs Leukemia Effect / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000276:immunology* / Q000628:therapy*; D017710:Lymphocyte Transfusion / Q000009:adverse effects / Q000379:methods; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000276:immunology* / Q000628:therapy*; D019233:Retreatment; D014019:Tissue Donors; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D006680:HLA Antigens